Table 1.
Patient, Disease and Treatment Characteristics
| Patient Characteristics | N = 88 | % | |
|---|---|---|---|
| Gender | Female: Male | 55:33 | 63%: 37 |
| Age at Diagnosis (months) | Median (range) | 26.6 (1.4–162.6) | |
| Associated NF1 | Presence of NF1 | 21 | 24 |
| Diencephalic Syndrome | Presence of diencephalic syndrome | 25 | 28 |
| Disease Characteristics | |||
| Tumor Site and Staging | Non-optic pathway glioma (OPG) | 11 | 12 |
| Optic pathway glioma (OPG) | 77 | 88 | |
| Optic Pathway Tumor Staging | Optic nerve/s +/- Chiasm (MDC 1/2) | 34 | 44 |
| Post-chiasmatic (MDC 3) | 31 | 40 | |
| Optic tracts (MDC 4) | 12 | 16 | |
| Hypothalamic involvement | 59 | 67 | |
| Metastatic Disease | Yes | 17 | 19 |
| No | 71 | 81 | |
| Histology (71 Patients) | Pilocytic astrocytoma (PA) | 58 | 82 |
| Non-pilocytic astrocytoma (Non-PA) | 13 | 18 | |
| BRAF Status (60 Patients) | BRAF-V600E mutation | 12 | 20 |
| BRAF:KIAA1549 fusion | 29 | 48 | |
| BRAF wild-type (WT) | 18 | 30 | |
| Other | 1 | 2 | |
| Pre-Bevacizumab Therapy Treatments | |||
| Surgical Intervention | Biopsy only | 36 | 41 |
| Resection/debulking | 33 | 38 | |
| No intervention | 19 | 21 | |
| Chemotherapy | Received chemotherapy | 81 | 92 |
| Bevacizumab Therapy Data | |||
| Indication for Bevacizumab Treatment | Clinical progression | 18 | 20 |
| Radiological progression | 38 | 44 | |
| Both | 24 | 27 | |
| Other | 8 | 9 | |
| Age at Starting Bevacizumab (months) | Median (range) | 73.5 (6.6–257) | |
| Number of Bevacizumab Doses | Median | 24 (2–49) | |
| Bevacizumab Partner Drug | Irinotecan | 76 | 86 |
| Vincristine-carboplatin | 7 | 7 | |
| Vinblastine | 2 | 2 | |
| Other (or monotherapy) | 3 | 3 | |
| Bevacizumab Line of Treatment | 1st-line (with VCR + carboplatin) | 7 | 8 |
| 2nd-line (with VBL or irinotecan) | 6 | 7 | |
| 3rd-line (with irinotecan) | 61 | 70 | |
| Further than 3rd-line | 14 | 16 |